Endocrine-Related Cancer
Endocrine-Related Cancer is the journal of the Society for Endocrinology, published by the society's own publishing arm BioScientifica and issued monthly. It concentrates on endocrine tumours and hormone-dependent cancers, spanning basic mechanism to clinical translation, and is among the principal dedicated titles in endocrine oncology.《内分泌相关癌症》（Endocrine-Related Cancer）是英国内分泌学会（Society for Endocrinology）的机关刊，由学会旗下的 BioScientifica 出版，月刊发行。该刊聚焦内分泌肿瘤与激素依赖性癌症，覆盖从基础机制到临床转化的全链条研究，是内分泌肿瘤领域最主要的专门刊物之一。
Scope
Endocrine-Related Cancer takes cancers of the endocrine system as its object, declining general oncology contributions in favour of a scope organised by anatomical site and hormone-dependent tissue. Its principal subject areas include:Endocrine-Related Cancer 的取稿立场是「以内分泌系统的癌症为对象」，不收泛肿瘤学的通用稿件，刊载范围按解剖部位与激素依赖性组织划分，界限相当明确。收文范围覆盖的主要方向包括：
- Tumours of endocrine glands: cancers of the adrenal, breast, thyroid and parathyroid glands, the pituitary, the testis and the ovary, together with multiple endocrine neoplasia syndromes.内分泌腺体肿瘤： 肾上腺、乳腺、甲状腺、甲状旁腺、垂体、睾丸与卵巢肿瘤，以及多发性内分泌腺瘤综合征。
- Neuroendocrine tumours: the genetics and molecular mechanisms of neuroendocrine tumours, phaeochromocytomas and paragangliomas, the direction most identified with the journal.神经内分泌肿瘤： 神经内分泌肿瘤、嗜铬细胞瘤与副神经节瘤的遗传与分子机制，是该刊最具标识性的方向。
- Hormone-dependent cancers: hormone-receptor signalling, hormone-deprivation therapy and endocrine resistance mechanisms, with hormone-sensitive tumours such as prostate cancer.激素依赖性癌症： 激素受体信号、激素剥夺治疗与内分泌耐药机制，以及前列腺癌等激素敏感肿瘤。
- Metabolism-related cancers: tumours affecting metabolism and energy generation, addressing endocrine mechanisms in cancers of the bladder, bone, kidney, lung and head and neck.代谢相关肿瘤： 影响代谢与能量生成的肿瘤，包括膀胱、骨、肾、肺与头颈部肿瘤中的内分泌机制。
- Reviews and guidelines: the journal carries mini-reviews, systematic reviews and clinical guidelines and recommendations, with reviews occupying a prominent place.综述与指南： 刊载小型综述、系统综述以及临床指南与推荐，综述在本刊占有重要位置。
Manuscript types include research articles, reviews, guidelines and recommendations, editorials, letters and case reports, submitted through ScholarOne. Peer review is double-anonymised and no pre-submission enquiry is required. The journal is hybrid open access, with an article processing charge of three thousand pounds, halved for authors at non-profit subscribing institutions稿件类型包括研究论文、综述、指南与推荐、社论、通讯与病例报告，经 ScholarOne 系统投稿，同行评审采用双盲方式，不设投稿前询问环节。该刊为混合开放获取，文章处理费三千英镑，非营利订阅机构作者减半；作者录用稿可存入机构库实现绿色开放获取，订阅内容满五年自动免费。 accepted manuscripts may be deposited in institutional repositories as green open access, and subscription content becomes free five years after publication.[1]
History
- Precursor and founding (1978/1994): the journal's lineage begins with the in-house industrial publication Reviews on Endocrine-Related Cancer (1978-1993), which the society took over in 1994 and renamed Endocrine-Related Cancer, widening its scope from reviews to original research.前身与创刊（一九七八年／一九九四年）： 本刊的刊脉起点是化学企业内部的《内分泌相关癌症评论》（Reviews on Endocrine-Related Cancer，一九七八至一九九三年），由学会于一九九四年接管并改为现名，收稿范围从综述扩展至原创研究。[2]
- Publisher transition: publication began under the society's Journal of Endocrinology Ltd. in 1994 and moved in January 2011 to BioScientifica, the society's wholly owned publishing subsidiary, giving the present arrangement of publication on the society's behalf.出版方沿革： 一九九四年起由学会的出版机构 Journal of Endocrinology Ltd. 出版，二〇一一年一月起改由学会全资子公司 BioScientifica 出版，形成现行的「代表学会出版」格局。[3]
- Frequency evolution: the journal began at four issues a year in 1994, moved to bimonthly in 2011 and to monthly around 2016刊期演变： 一九九四年创刊时为每年四期，二〇一一年起改为双月刊，约二〇一六年以后升为月刊；部分目录中仍存的季刊记录已经过时。 the quarterly frequency still found in some catalogues is out of date.[4]
- Adoption by societies: the European Society of Endocrinology adopted the journal in 2006, the Endocrine Society of Australia in 2014 and the Japanese Hormone and Cancer Society in 2015, giving it multi-society support.学会采纳： 欧洲内分泌学会于二〇〇六年、澳大利亚内分泌学会于二〇一四年先后将其采纳为机关刊，日本激素与癌学会于二〇一五年跟进，形成多学会共同支持的格局。[5]
- Metric standing: the 2025 impact factor is 4.4, with a five-year figure of 4.2, placing the journal in the second quartile of both endocrinology and metabolism and oncology.指标走势： 二〇二五年影响因子四点四，五年影响因子四点二，在内分泌学与代谢、肿瘤学两个小类均列二区。[6]
Editors
The journal operates under an editor-in-chief supported by one deputy editor and four advisory editors, a deliberately compact board oriented around subject oversight. Manuscripts go through the society's own system and double-anonymised review本刊实行主编统筹的编辑架构，配一名副主编与四名顾问编辑，编委规模不大、以专题把关为主。稿件经学会自有系统投递并作双盲评审；官方公布的唯一时效目标是「同行评议文章的首次决定力争两周内作出」，出版方不公布录用比例。 the only published timing target is that a first decision on a peer-reviewed article should be returned within two weeks, and no acceptance rate is published.[7]
- Karel Pacak (editor-in-chief since January 2026): director of the Center for Adrenal Endocrine Tumors at AKESO in the Czech Republic and formerly of the United States National Institutes of Health, known for work on the genetic mechanisms of phaeochromocytoma and paraganglioma.卡雷尔·帕察克（二〇二六年一月起任）： 捷克 AKESO 肾上腺内分泌肿瘤中心主任，原美国国立卫生研究院研究员，以嗜铬细胞瘤与副神经节瘤的遗传机制研究闻名。[8]
- Matthew Ringel (until the end of 2025): an endocrine oncology specialist at the Ohio State University, succeeded by Pacak at the start of 2026.马修·林格尔（至二〇二五年底）： 美国俄亥俄州立大学内分泌肿瘤专家，二〇二六年初由帕察克接任。[8]
- Earlier editors: the founding editor was Vivian James (1994-2000), followed in turn by Marc Lippman, James Fagin (2006-2010) and Charis Eng.早期主编谱系： 创刊编辑为维维安·詹姆斯（一九九四至二〇〇〇年），其后依次为马克·利普曼、詹姆斯·费金（二〇〇六至二〇一〇年）与卡里斯·恩格。[9]